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Abstract 
Background: The World Health Organization has recommended rapid diagnostic tests (RDTs) for use in the diagnosis 
of suspected malaria cases. In addition to providing quick and accurate detection of Plasmodium parasite proteins 
in the blood, these tests can be used as sources of DNA for further genetic studies. As sulfadoxine-pyrimethamine 
is used currently for intermittent presumptive treatment of pregnant women in both Senegal and in the Comoros 
Islands, resistance mutations in the dhfr and dhps genes were investigated using DNA extracted from RDTs.
Methods: The proximal portion of the nitrocellulose membrane of discarded RDTs was used for DNA extraction. This 
genomic DNA was amplified using HRM to genotype the molecular markers involved in resistance to sulfadoxine-
pyrimethamine: dhfr (51, 59, 108, and 164) and dhps (436, 437, 540, 581, and 613). Additionally, the msp1 and msp2 
genes were amplified to determine the average clonality between Grande-Comore (Comoros) and Thiès (Senegal).
Results: A total of 201 samples were successfully genotyped at all codons by HRM; whereas, in 200 msp1 and msp2 
genes were successfully amplified and genotyped by nested PCR. A high prevalence of resistance mutations were 
observed in the dhfr gene at codons 51, 59, and 108 as well as in the dhps gene at codons 437 and 436. A novel 
mutant in dhps at codon positions 436Y/437A was observed. The dhfr I164L codon and dhps K540 and dhps A581G 
codons had 100 % wild type alleles in all samples.
Conclusion: The utility of field-collected RDTs was validated as a source of DNA for genetic studies interrogating 
frequencies of drug resistance mutations, using two different molecular methods (PCR and High Resolution Melting). 
RDTs should not be discarded after use as they can be a valuable source of DNA for genetic and epidemiological stud-
ies in sites where filter paper or venous blood collected samples are nonexistent.
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Background
Malaria remains a major public health problem as it is 
responsible for 207 million cases and 627,000 deaths 
worldwide [1]. Currently, 90 % of the deaths attributable 
to this infection occur in sub-Saharan Africa. To com-
bat this disease, many programmes have implemented 
control measures such as the distribution of long-lasting 
insecticide-treated mosquito nets, the use of artemisinin-
based combination therapy (ACT) for the treatment of 
uncomplicated Plasmodium falciparum malaria, and the 
introduction of rapid diagnostics tests (RDTs) in health 
facilities for malaria diagnosis. Such interventions have 
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contributed to a dramatic drop in malaria-attributable 
deaths worldwide [1].
Widespread RDT use has greatly assisted in the accu-
rate diagnosis of presumed malaria cases in regions 
where microscopy (or molecular methods) are non-exist-
ent. RDTs are based on antigen detection and these anti-
gens, as well as parasite DNA, remain on the discarded 
RDT after it has been used for patient diagnosis. The 
widespread use of RDTs for diagnosis creates a valuable 
resource for population-based studies as RDTs have been 
shown to be suitable material for genetic studies, as DNA 
can be extracted from RDTs [2–5].
To validate the utility of field-collected RDTs for typ-
ing of drug resistance markers, two markers involved in 
sulfadoxine-pyrimethamine (SP, Fansidar®) resistance 
were selected: dhfr and dhps genes, as these both drugs 
are routinely used in the populations of interest (Senegal 
and Comoros). Until recently, SP was one of the main 
molecules for the treatment of uncomplicated malaria 
[6, 7]. However, resistance to SP has evolved quickly [8]. 
SP is a combination of two drugs that act at two suc-
cessive stages of the parasite folate pathway. Sulfadox-
ine inhibits the dihydropteroate synthetase gene (dhps), 
while pyrimethamine inhibits dihydrofolate reductase 
gene (dhfr). Point mutations in the dhfr and dhps genes 
confer resistance to pyrimethamine and sulfadoxine, 
respectively, with a decrease of in  vitro susceptibility of 
P. falciparum in relation to the number of mutations of 
each gene [9–13]. Although this molecule has seen a rela-
tive decline of its therapeutic efficacy, it is now used in 
Senegal for the Intermittent Preventive Treatment (IPT) 
of pregnant women and children against malaria, and in 
Comoros, for IPT of pregnant women, a policy change 
that was implemented in 2003 and 2004, respectively.
While many studies measuring the prevalence of dhfr 
and dhps mutations have been conducted previously in 
Senegal [14–19], few have been performed in Comoros 
[20–22], largely due to a lack of clinical studies in which 
venous blood or filter paper are collected to study para-
site molecular markers. The objectives of this study were 
(1) to assess the feasibility of DNA extraction from field-
collected RDTs, (2) to study gene mutations dhfr (S108N, 
N51I, C59R and I164L) and dhps (A437G, S436F, K540E, 
A581G and A613T/S) from samples of Senegal and 
Comoros with high-resolution melting technology and 
compare the prevalence between these two countries. 
Msp typing was used as a tool to compare the average 
multiplicity of infection between the two countries.
Methods
Study sites and sample collection
The Comoros islands are located on the southeastern 
coast of Africa in the Mozambique canal, and represent 
a country where malaria transmission is high [23]. 
In Grand-Comore, the largest of the four islands of 
Comoros, the malaria transmission is meso- to hyper-
endemic (EIR between 10 and 200) [20]. In contrast, 
Senegal has Sahalien characteristics marked by a trans-
mission that is seasonal and short. Samples collected for 
this study were from Thiès, an urban area 70 km east of 
Dakar, where malaria is hypoendemic [24], with an EIR 
between 1 and 5.
In Grande-Comore, RDT samples were collected from 
2012 to 2013 by the National Malaria Control Programme 
in the city of Moroni, where malaria is hypoendemic; and 
in two hospitals Mitsamiouli and Mbeni where malaria 
is mesoendemic and meso to hyperendemic respectively 
[20]. In Senegal, RDT samples were collected in 2010 at 
the Service de Lutte Anti-Parasitaire (SLAP) clinic, in 
Thiès. Malaria positive RDTs were stored at room tem-
perature with desiccant at both sites.
Rapid diagnostic tests and DNA extraction
In Senegal, SD BIOLINE Malaria rapid test for Pf alone 
(SD Bioline, 05FK50) was used while in Comoros two 
different tests were used: Malaria pLDH/HRP2 Combo 
(Access Bio, PBX-KM30003) and SD BIOLINE Malaria 
Ag Pf/Pan (SD Bioline, 05FK60). The proximal third of 
the nitrocellulose membrane was chosen for DNA extrac-
tion as previously described [2]. DNA was extracted 
with the QIAamp DNA Mini kit (Qiagen) according to 
the manufacturer’s recommendations for filter paper. 
In total, 204 samples (124 from Grande-Comore and 80 
from Thiès) were extracted and genotyped.
Single nucleotide polymorphism analyses by high 
resolution melting
SNP analysis for mutations in dhfr (S108N, N51I, C59R 
and I164L) and dhps (A437G, S436F, K540E, A581G and 
A613T/S) genes were conducted by High Resolution 
Melting (HRM) analysis using a Light Scanner LS-32, 
according to previously published methodology [18]. 
Asymmetric PCR was performed with final primer con-
centrations of 0.25 µM reverse primer; 0.05 µM forward 
primer; and a final probe concentration of 0.02 µM. The 
cycling and melting conditions for dhps amplification 
were as follows: 95  °C denaturation for 1  min, followed 
by 55 cycles of (95 °C for 5 s and 66 °C for 30 s) a pre-melt 
cycle of 5 s each at 95  °C and 37  °C, followed by a melt 
from 45 to 90  °C at a 0.30  °C/s. For the 437 dhps assay, 
cycling and melting conditions were as follows: 95  °C 
denaturation for 1  min, followed by 55 cycles of (95  °C 
for 5 s, 66 °C for 30 s, 74 °C for 30 s) a pre-melt cycle of 
5 s each at 95 and 37  °C, followed by a melt from 45 to 
90 °C at a 0.30 °C/s. The cycling and melting conditions 
for dhfr amplification were as follows: 95 °C denaturation 
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for 1 min, followed by 55 cycles of (95 °C for 5 s, 56 °C for 
30 s) a pre-melt cycle of 5 s each at 95 and 37 °C, followed 
by a melt from 45 to 90 °C at a 0.30 °C/s.
DNA sequencing
PCR sequencing (Sanger sequencing) of the dhps 436/437 
amplicon was performed by using the same primers 
used in the HRM reaction (Forward: GAATGTTTG 
AAATGATAAATGAAGGTGCTA and Reverse: CAGG 
AAACAGCTATGACGAAATAATTGTAATACAGG 
TACTACTAAATCTCT). Sequencing was performed in 
both the forward and the reverse direction by Macrogen 
and contigs were assembled using Lasergene 10.
Allelic typing of Plasmodium falciparum msp1 and msp2
The polymorphic regions (block 2 of MSP1 and block 3 
of MSP2) were amplified as previously described [25]. All 
PCR reactions were carried out in a total volume of 20 µl 
containing 6 µl Gotaq, 0.5 µM of each primer, and 11 µl 
reagent grade water. In the first round reaction (nest 1), 
1 µl of genomic DNA was added as a template. In the sec-
ond nested reaction (nest 2), 1 µl of the nest 1 PCR prod-
uct was used as DNA template.
The cycling conditions for the nest 1 PCR were as fol-
lows: initial denaturation at 95 °C for 5 min, followed by 
35 cycles of (94 °C for 1 min, 58 °C for 2 min, 72 °C for 
2 min), with a final extension cycle of 72 °C for 3 min. The 
cycling conditions for the nest 2 PCR were as follows: ini-
tial denaturation at 95 °C for 5 min, followed by 35 cycles 
of (94  °C for 1  min, 61  °C for 2  min, 72  °C for 2  min), 
with a final extension cycle of 72  °C for 3  min. Positive 
controls (3D7 for K1 and IC27 alleles, Dd2 for MAD20 
and FC27 alleles, and 7G8 for the RO33 allele) and nega-
tive control (reagent grade water alone) were run in each 
PCR reaction. PCR products were analyzed on 2 % aga-
rose gels stained with ethidium bromide and visualized 
by UV trans-illumination (BioradGel Doc™  XR  +  Sys-
tem with Image  Lab). The size of resulting DNA bands 
were approximated using Gene Ruler 100 bp DNA ladder 
marker (Quick Load).
Statistical analyses
Statistical analyses were performed using the Z-test for 
two population proportions to compare mutant allele 
prevalence between Comoros and Senegal samples. For 
all tests, the significance level was α = 0.05.
Results
The prevalence of mutations in dhfr and dhps
Genotyping of dhps and dhfr genes was performed for 
201 samples (n  =  124 for Grande-Comore and n  =  77 
for Thiès). For dhfr codons 51/59, only 62 samples from 
Thiès and 96 samples from Grande-Comore yielded a 
successful genotyping result; whereas at all other loci, 
genotyping was successful for all samples (Table 1).
In Thiès, for the dhfr gene, 90  % (54/60) of the sam-
ples had the mutant allele at codons dhfr N51C/C59R, 
and 95.8  % (68/71) had the mutant allele at codon dhfr 
S108 N. For the dhps gene 1.33 % (1/75) had the A613T 
mutant allele and 53.9 % (41/76) of the samples had the 
A437G mutant allele. At the S436 codon of dhps 12  % 
(9/77) of the samples had the mutant allele S436F, a 
recently characterized mutation described previously 
[18]. For all other codons (namely, dhfr I164, dhps K540, 
and dhps A581) 100 % of the samples had the wild-type 
allele. Previously unreported mutations were observed 
for dhps gene at codons 436/437 by HRM (Fig.  1a) and 
were confirmed to be S436Y/437A by Sanger sequencing 
(Fig. 2).
In Grande-Comore, for the dhfr gene, 93.4 % (115/123) 
had the S108 N mutation, 62.5 % (60/96) of the samples 
had the N51I mutant allele, and 69.8  % (67/96) of all 
samples had the C59R mutant allele. For the dhps gene, 
at position A437, 29.8  % (37/124) of samples had the 
mutant allele A437G. For all other codons (namely, dhfr 
I164, dhps K540, dhps A581, dhps A613, and dhps S436), 
100 % of the samples had the wild-type allele.
A statistically significant difference was observed in 
the prevalence of mutations between the Comoros and 
Senegal for the dhfr gene codons 51 (0.0001), and 59 
(p = 0.003), and dhps gene codons 436 (p = 0.0001) and 
Table 1 Utility of RDTs as a source of DNA for genotyping loci involved in diversity and drug resistance
a The HRM method was used for genotyping dhfr and dhps genes
b PCR was used to genotype msp1 and msp2
c For codons 51/59, only 62 samples from Thiès and 96 samples from Grande-Comore gave a comprehensive genotyping
RDT Brand Number RDT HRMa HRMa PCRb PCRb Fragment used RDT
Positive Negative Positive Negative
SD Bioline malaria Rapid test pf 80 77 3 77 3 1/3 NC
SD Bioline malaria Ag Pf/Pan 13 13 0 13 0 1/3 NC
Malaria pLDH/HRP2 combo 111 111 0 110 1 1/3 NC
Total 204 201c 3 200 4 –
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Fig. 1 HRM peak profiles for wild-type and mutant dhps 436/437 alleles. a The 3D7 peak represents the profile for the wild-type at codon 436 and 
mutant profile for the 437 codon. The Dd2 peak presents the profile for the two mutant Codons 436/437. The HB3 peak presents the wild-type 
profile of the two codons. The 436A/437A peaks, represented the mutations found by Daniels et al. in Senegal [18]. The blue peak from sample Th50 
RDT represents a new mutant allele. b The peaks C03 and C05 represent mixed samples (mutant + wild). The Dd2 peak presents the mutant profile 
for both codons 436 and 437. The HB3 peak represents the wild-type profile for both codons 436 and 437. The 3D7 peak represents the profile for the 
wild-type at codon 436 and mutant profile for the 437 codon
Page 5 of 8Papa Mze et al. Malar J  (2015) 14:373 
437 (p  =  0.0007). The prevalence of mutations on the 
dhfr gene at codon 51 and 59 and dhps gene at codon 
436 and at codon 437 were higher in Thiès compared to 
Grande-Comore.
The single mutation (S108N alone, in the absence of 
other dhfr mutations) was not found in Thiès; whereas, in 
Grande-Comore it was present at 1.6 % (2/122) (Fig. 3). 
The prevalence of the double mutation (dhfr C59R and 
S108N) was 9  % (6/67) in Thiès and 25.4  % (31/122) in 
Grande-Comore (Fig.  3). However, the triple mutation 
(dhfr S108N, N51I, and C59R) was present at similar 
prevalences in both countries with 44.3  % (28/122) in 
Grande-Comore and 42 % (28/67) in Thiès; whereas the 
quadruple mutation (dhfr S108N, N51I, C59R, and dhps 
A437G) was observed at 28.7  % (35/122) in Grande-
Comore and 49 % (33/67) in Thiès (Fig. 3). No quintuple 
mutations (dhfr S108N, N51I, C59R, dhps A437G, and 
K540E) were observed in either country. Statistically, 
there was no significant difference in the prevalence of 
single (p  =  0.29) and triple mutation (p  =  0.74); how-
ever there was significance difference in the prevalence of 
double mutation (p =  0.0063) and the quadruple muta-
tion (p = 0.0048) between the two countries using Z-test 
for 2 population proportions (Fig. 3).
When comparing the number of mixed alleles 
(mutant + wild) detected by HRM, overall mixed alleles 
were more prevalent in Grande-Comore samples than in 
samples from Thiès. An example of the HRM output for 
mixed alleles is shown in Fig. 1b. The difference in mixed 
alleles at dhfr position 108 and dhps position 437 was not 
significantly different between the two sites [dhfr 108: 
Grande-Comore 4 mixed samples (3  %); Thiès 3 mixed 
Fig. 2 Sequencing sample Th050. a DNA; b amino acid. To confirm the new mutant profile obtained from HRM, sequencing was performed. After 
alignment of the nucleotides sequences we found new mutations in dhps 436Y/437A. The TAT codon corresponds to tyrosine (Y) and the codon 
GCT corresponding to the alanine (A)
Fig. 3 Prevalence of single, double, triple, quadruple and quintuple mutation, in Comoros and Senegal. The prevalence of single (S108N), double 
(S108N/C59R), triple (N51I/C59R/S108N), quadruple (N51I/C59R/S108N/A437G) and quintuple (N51I/C59R/S108N/A437G/K540E) mutation was 
determined by counting the number of mutants present only in one, two, three, four or five Codons respectively. The Z-test for two population 
proportions is used to determine the P values, with a significance level of α = 0.05
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(4  %) samples (p  =  0.77); dhps 437: Grande-Comore 
5 mixed samples (4  %); Thiès 2 mixed samples (2.6  %) 
(p = 0.60)]. In contrast, in Grande-Comore a significant 
difference in the prevalence of mixed alleles at dhfr 51/59 
was observed. In Grande-Comore, 27 mixed samples 
(28 %) at dhfr codons 51/59 compared to six mixed sam-
ples (9 %) in Thiès (p = 0.003) were observed.
Genotyping using msp1 and msp2
Having validated the RDT-extracted DNA to study 
markers of drug resistance, the average clonality in both 
populations was determined by msp typing. With sam-
ples from Thiès, a total of 77 samples were positive for 
msp1 and msp2 genes, with 3 samples failing to amplify 
(Table  1). In total, 36 samples (64.2  %) contained poly-
clonal infection at least with 2 clones. The average mul-
tiplicity of infection (MOI) for all isolates from Thiès was 
estimated to be 1.57.
With samples from Grande-Comore, a total of 123 
samples were positive for msp1 and msp2 genotyping, 
with only a single sample failing amplification (Table 1). 
In total, 42 samples (43.7 %) had polyclonal infections at 
least with 2 clones. The average multiplicity of infection 
(MOI) was 1.47.
Discussion
The WHO recommends that all suspected malaria cases 
be confirmed by RDTs. RDTs facilitate the diagnosis of 
malaria by providing evidence of the presence of specific 
Plasmodium antigens in human blood without the need 
for electricity or advanced microscopy training. Previ-
ous studies have shown that it is possible to extract Plas-
modium DNA from RDTs [2, 3, 5]. This study sought to 
address whether the use of stored, discarded RDTs from 
field sites can serve as source of DNA for genomic studies 
in populations in which whole blood or filter paper-based 
DNA samples are unavailable.
There are many factors that could affect the efficacy of 
extracting DNA from field-based RDTs. Some of these 
factors include variable preparation of RDTs (variable 
blood volumes), and storage conditions. Storage condi-
tions in field sites can differ, introducing the possibility of 
bacterial or fungal contamination as well as DNA degra-
dation. Another variable to consider is the proportion of 
human DNA to Plasmodium DNA on each RDT as the 
ability to detect Plasmodium genes will depend on the 
specific concentration of Plasmodium DNA. Taking all 
these field-based realities into consideration, the meth-
odology outlined by Cnops et  al. [2] was applied to the 
field as overall, RDTs represent a cost-efficient method 
for the conservation, transport, and storage of DNA sam-
ples. This study addresses the reality of using RDTs from 
malaria endemic sites as sources of genetic material for 
performing molecular studies.
To test the performance of field-RDT extracted DNA 
for genetic experiments, two genetic methodologies 
were employed: high resolution melting (HRM) for drug 
resistance markers (dhfr and dhps) and msp typing by 
PCR to determine clonality. Differences in malaria trans-
mission reported between Grande-Comore (meso-hyper-
endemic) and Thiès (hypoendemic) were compared by 
msp typing, and a small, but insignificant difference was 
observed in the multiplicity of infection for msp genes 
(msp1 and msp2) (MOI = 1.57 in Thiès and MOI = 1.47 
in Grande-Comore). This small difference is interest-
ing given the predicted higher endemicity of Grande-
Comore compared to Thiès.
HRM is a method that uses post-PCR melting analy-
sis used to identify SNPs in nucleic acid sequences, and 
has a limit of detection of 100  fg of DNA [18]. In this 
study, successful genotyping by HRM was performed 
from DNA extracted from RDTs. An additional meth-
odological advantage of HRM is that known mutations 
can be classified and novel mutations can be identified, 
such as the 436Y/437A mutations in dhps, which were 
identified in a sample from Thiès (Fig. 1a). When results 
are compared from RDT-extracted DNA to previous 
results obtained with the filter-paper extracted DNA 
using the same HRM method from the same population 
(Thiès, Senegal), similar frequencies for dhfr mutations at 
codons 51, 59 and 108 and dhps mutations at codon 437 
[18] were observed.
Having confidence in the results obtained for Thiès, 
Senegal, this validated approach was applied to a popu-
lation lacking filter paper or venous blood DNA sam-
ples: Comoros. In 2005, with declining CQ efficacy in 
Comoros, SP monotherapy efficacy studies were per-
formed and while SP showed good clinical and parasi-
tological responses (90–100  %), concerns were raised 
regarding the high prevalence of dhfr S108N mutations 
[21, 22]. In 2003, CQ was the first line treatment for 
malaria, with SP as the second-line drug. In 2005, CQ 
was replaced by artemether–lumefantrine for treat-
ment of clinical malaria, although SP is still used for IPT 
in pregnant women to date. Very few molecular stud-
ies of drug resistance markers have been published for 
Comoros [20–22]. Interestingly, the number of mutations 
in Grande-Comore were significantly higher in this study 
(2012–2013) compared to what was shown by Rebaudet 
et al. [20] (Additional file 1: Table S1), specifically at dhfr 
codon 51 (38.5 % in 2010 compared to 62.5 % in 2012–
2013; p  =  0.02), dhfr position 108 (50  % in 2010 com-
pared to 93  % in 2012–2013; p  <  0.05) and dhps codon 
437 (4  % in 2010 compared to 29.8  % in 2012–2013; 
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p = 0.006). A significant increase in the number of mixed 
alleles at dhfr C59 and C59R (7.7 % in 2010 compared to 
28 % in 2012–2013; p = 0.03) was observed and a trend-
ing increase in the number of mixed alleles at dhps A437 
and A437G (Fig. 1b); albeit non-significant (0 % in 2010 
compared to 4  % in 2012–2013, p  =  0.3) (Additional 
file 1: Table S1). However; a decrease in mixed alleles dhfr 
S108 and S108 N (15.4 % in 2010 compared to 3.25 % in 
2012–2013; p =  0.01) was observed. Of concern, a sta-
tistically significant increase in the triple mutation dhfr 
N51I/C59R/S108 N (50 % in 2010 compared to 89.6 % in 
2012–2013; p  <  0.05) was observed in this study. Other 
studies performed in Comoros in 2004–2006 [26] and 
2006 [27] showed similar triple mutation frequencies (53 
and 45  %, respectively) to the 50  % reported by Rebau-
det et al. [20], indicating a very recent increase in triple 
mutation prevalence.
This high prevalence of mutations could potentially be 
explained by the use of SP for IPT but also by the fact that 
SP has been used as treatment for uncomplicated malaria 
[28]. On the other hand, the widespread use of trimeth-
oprim-sulfamethoxazole (Cotrimoxazole® or Bactrim®) 
in Comoros, a drug similar to SP that has the ability to 
select for resistant mutants [29, 30] could also potentially 
explain the higher frequencies of mutant alleles between 
2010 and 2012/2013.
Drug resistance mutations highly associated with drug 
failure in both countries were compared, and encourag-
ingly, the quintuple mutant dhfr 51I/59R/108N  +  dhps 
437G/540E which is a key mutation associated with 
clinical failure to SP [31, 32] was not observed, in either 
Grande-Comore or in Thiès, Senegal. This lack of the 
quintuple mutation has been reported in previous stud-
ies [14–19], with the exception of one study by Andriant-
soanirina et al. where a 0.4 % prevalence of the mutation 
A437G/K540E was observed in Comoros [27]. While, 
SP can be still used for ITP as recommended by World 
Health Organization [33], vigilance is needed as the 
WHO recommends replacing SP monotherapy if the 
prevalence of the K540E mutation exceeds 50  % in the 
population [33, 34]. These results taken together suggest 
that yearly monitoring of SP drug resistance in Comoros 
needs to be a policy priority as it will be important to 
assess the future efficacy of SP as a drug for IPT.
Conclusion
In conclusion, drug resistance monitoring in Comoros is 
a critical area of future ongoing research. DNA extracted 
from RDTs can be a useful source of DNA for genetic 
epidemiological studies. DNA extracted from RDTs can 
be an alternative to filter paper or venous blood when 
such samples are not available.
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